The expression of a mutant epidermal growth factor receptor in prostatic tumours

BJU International

Volumn 87, Issue 3, 2001, Pages 224-226

  Olapade Olaopa, E O ^a,b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b FRCS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION;

BLOTTING, WESTERN; DISEASE PROGRESSION; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 0035129610     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02036.x     Document Type: Article

References (12)

1. Epidemiology of prostate cancer
2. Peptide growth factors in the prostate as mediators of stromal epithelial interaction
3. Epidermal growth factor receptors in prostate cancer: Correlation with histological differentiation of the tumour
4. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue
5. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy
6. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours
7. Evidence for the differential expression of a variant EGF receptor in human prostate cancer
8. Further characterisation of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multi-centre immunohistochemical studies
9. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
10. Current prognostic factors for prostate carcinoma
11. Cell proliferation assessed by Ki-67 immunoreactivity on formalin -fixed tissues is a predictive factor for survival in prostate cancer